The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Schastlivtsev I.V.

Department of General Surgery and Radiodiagnostics, State budgetary educational institution of higher professional education «N.I. Pirogov Russian National Research Medical University»;
Clinical Hospital No 1 (Volynskaya), General Management Department of the Presidential Administration

Lobastov K.V.

Kafedra obshcheĭ khirurgii lechebnogo fakul'teta GOU VPO RGMU Roszdrava, Moskva

Tsaplin S.N.

Department of General Surgery and Radiodiagnostics, State budgetary educational institution of higher professional education «N.I. Pirogov Russian National Research Medical University»;
Clinical Hospital No 1 (Volynskaya), General Management Department of the Presidential Administration

Kanzafarova I.Yu.

Pirogov Russian National Research Medical University of Ministry of Health of Russia, Moscow, Russia

Barinov V.E.

klinika MEDSI "Amerikanskiĭ meditsinskiĭ tsentr", Moskva

Laberko L.A.

Kafedra obshcheĭ khirurgii lechebnogo fakul'teta Rossiĭskogo nauchno-issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Rodoman G.V.

State clinical hospital №24, Moscow city health department

Zhuravlev S.V.

Clinical Hospital №1 of the Presidential Administration of the Russian Federation, Moscow, Russia

Rivaroxaban in the Treatment of Deep Vein Thrombosis of The Upper Extremities: Single-CenterExperience

Authors:

Schastlivtsev I.V., Lobastov K.V., Tsaplin S.N., Kanzafarova I.Yu., Barinov V.E., Laberko L.A., Rodoman G.V., Zhuravlev S.V.

More about the authors

Journal: Journal of Venous Disorders. 2019;13(2): 124‑132

DOI: 10.17116/flebo201913021124

Views: 3510

Downloaded: 107

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Schastlivtsev IV, Lobastov KV, Tsaplin SN, et al. . Rivaroxaban in the Treatment of Deep Vein Thrombosis of The Upper Extremities: Single-CenterExperience. Journal of Venous Disorders. 2019;13(2):124‑132. (In Russ.)
https://doi.org/10.17116/flebo201913021124

Подписка 2025 (Journal of Venous Disorders)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Lymphatic Outflow and Correction of Appropriate Diso­rders in Patients with Venous Thro­mbosis and Chro­nic Venous Disease. Journal of Venous Diso­rders. 2024;(1):26-31
Effi­cacy and Safety of Different Anti­coagulation Regi­mens for Deep Vein Thro­mbosis in Real Clinical Practice. Journal of Venous Diso­rders. 2024;(2):89-99
Venous Thro­mboembolism in Women with Chro­nic Venous Disease of the Lower Extremities Receiving Direct Oral Anti­coagulants for Atrial Fibrillation. Journal of Venous Diso­rders. 2024;(2):106-114
Effi­cacy and Safety of Different Anti­coagulation Regi­mens for Deep Vein Thro­mbosis in Real Clinical Practice. Journal of Venous Diso­rders. 2024;(2):89-99
Venous Thro­mboembolism in Women with Chro­nic Venous Disease of the Lower Extremities Receiving Direct Oral Anti­coagulants for Atrial Fibrillation. Journal of Venous Diso­rders. 2024;(2):106-114
Anti­coagulant Therapy Flaws in Hospitalized Patients with Proximal Deep Vein Thro­mbosis and Their Impact on the Treatment Outcomes. Journal of Venous Diso­rders. 2024;(3):178-184
Risk Factors of Bleedings in Patients with COVID-19 Receiving Anti­coagulants for Venous Thro­mboembolism Prevention. Journal of Venous Diso­rders. 2024;(3):222-231
Expe­rience of exoskeletal reha­bilitation of a patient with supe­rior flaccid mono­paresis caused by a gunshot wound after neurosurgical reco­nstruction of the branches of the brachial plexus. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(1):35-41

Aim — to evaluate the efficacy and safety of anticoagulant therapy with rivaroxaban for deep vein thrombosis of the upper extremities. Material and methods. A prospective observational trial included patients with the first episode of symptomatic deep vein thrombosis of the upper extremities. Enoxaparin (1 mg/kg twice a day) was initially administered in all patients for 24–48 h with following prescription of rivaroxaban: 15 mg twice a day for 3 weeks, then 20 mg once a day. There were 30 patients: 13 men and 17 women aged 28—78 years (mean age 52.4±17.3 years). The main criterion was symptomatic recurrent venous thromboembolic complication (VTEC). Results. All patients were followed-up during 6 months. Recurrent VTECs were not observed in any (0%) case ( 95% CI 0.0—11.4). Asymptomatic recurrences were also absent. Recanalization of venous segments was achieved in 100% of cases (95% CI 88.7—100.0). Signs of post-thrombotic disease of the upper extremities were noted in 4 (13.4%) cases (95% CI 5.4—29.8). Mean Villalta score was 2.1±1.9. No major bleeding was observed. Clinically significant bleeding developed in 2 (6.7%) patients (95% CI 1.9—21.4), minor bleeding — in 2 (6.7%) patients (95% CI 1.9—21.4). Overall incidence of bleeding was 13.4% (95% CI 5.4—29.8). Conclusion. Treatment of deep vein thrombosis of the upper extremities with rivaroxaban is associated with high efficacy and safety, adequate recanalization and low incidence of post-thrombotic disease.

Keywords:

venous thrombosis
upper extremities
post-thrombotic disease
anticoagulant therapy
rivaroxaban

Authors:

Schastlivtsev I.V.

Department of General Surgery and Radiodiagnostics, State budgetary educational institution of higher professional education «N.I. Pirogov Russian National Research Medical University»;
Clinical Hospital No 1 (Volynskaya), General Management Department of the Presidential Administration

Lobastov K.V.

Kafedra obshcheĭ khirurgii lechebnogo fakul'teta GOU VPO RGMU Roszdrava, Moskva

Tsaplin S.N.

Department of General Surgery and Radiodiagnostics, State budgetary educational institution of higher professional education «N.I. Pirogov Russian National Research Medical University»;
Clinical Hospital No 1 (Volynskaya), General Management Department of the Presidential Administration

Kanzafarova I.Yu.

Pirogov Russian National Research Medical University of Ministry of Health of Russia, Moscow, Russia

Barinov V.E.

klinika MEDSI "Amerikanskiĭ meditsinskiĭ tsentr", Moskva

Laberko L.A.

Kafedra obshcheĭ khirurgii lechebnogo fakul'teta Rossiĭskogo nauchno-issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Rodoman G.V.

State clinical hospital №24, Moscow city health department

Zhuravlev S.V.

Clinical Hospital №1 of the Presidential Administration of the Russian Federation, Moscow, Russia

List of references:

  1. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P., Folsom A.R. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004 Jul 1;117(1):19-25. https://doi.org/10.1016/j.amjmed.2004.01.018
  2. Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk ofvenous thromboembolism: prospective cohort study. BMJ. 2011 Aug 16;343:d4656. https://doi.org/10.1136/bmj.d4656
  3. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007 Apr;5(4):692-699. https://doi.org/10.1111/j.1538-7836.2007.02450.x
  4. Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, Becker RC, Goldberg RJ. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21:722-727. https://doi.org/10.1111/j.1525-1497.2006.00458.x
  5. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H. Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L, Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. https://doi.org/10.1016/j.chest.2015.11.026
  6. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl): 7S-47S. https://doi.org/10.1378/chest.1412S3
  7. Joffe HV, Kucher N, Tapson VF, Goldhaber SZ. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation. 2004;110(12):1605-1611. https://doi.org/10.1161/01.CIR.0000142289.94369.D7
  8. Munoz FJ, Mismetti P, Poggio R, Valle R, Baron M, Guil M, Monreal M. Clinical outcome of patients with upper extremity deep vein thrombosis: results from the REITE registry. Chest. 2008;133:143-148. https://doi.org/10.1378/chest.07-1432
  9. Isma N, Svensson PJ, Gottsäter A, Lindblad B. Upper extremity deep venous thrombosis in the population-based Malmö thrombophilia study (MATS). Epidemiology, risk factors, recurrence risk, and mortality. Thromb Res. 2010;125:e335-e338. https://doi.org/10.1016/j.thromres.2010.03.005
  10. Gloviczki P, Dalsing MC, Eklof B, Lurie F, Wakefield TW, Gloviczki ML. Handbook of Venous and Lymphatic Disorders. Guidelines of the American Venous Forum. Boca Raton: CRC Press; 2017.
  11. Illig KA, Doyle A. A comprehensive review of Paget — Schroetter syndrome. J Vasc Surg. 2010;51:1538-1547. https://doi.org/10.1016/j.jvs.2009.12.022
  12. Persson LM, Arnhjort T, Lärfars G, Rosfors S. Hemodynamic and morphologic evaluation of sequelae of primary upper extremity deep venous thromboses treated with anticoagulation. J Vasc Surg. 2006;43:1230-1235; discussion 1235. https://doi.org/10.1016/j.jvs.2006.02.045
  13. Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap ÁF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. The Lancet Haematology. 2014;1(1):e37-e46. https://doi.org/10.1016/S2352-3026(14)70018-3
  14. Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. The Lancet. Haematology. 2016;3(1):e12-e21. https://doi.org/10.1016/S2352-3026(15)00257-4
  15. Roussin A. Effective management of acute deep vein thrombosis: direct oral anticoagulants. Int Angiol. 2015;34:16-29.
  16. Baarslag H, van Beek EJ, Koopman MM, Reekers JA. Prospective Study of Color Duplex Ultrasonography Compared with Contrast Venography in Patients Suspected of Having Deep Venous Thrombosis of the Upper Extremities. Ann Intern Med. 2002;136(12):865-872. https://doi.org/10.7326/0003-4819-136-12-200206180-00007
  17. Anderson FAJr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003 Jun 17;107(23 Suppl 1):I9-16. https://doi.org/10.1161/01.CIR.0000078469.07362.E6
  18. Czihal M, Paul S, Rademacher A, et al. Impact of the postthrombotic syndrome on quality of life after primary upper extremity deep venous thrombosis. Vasa. 2012;41(3):200-204. https://doi.org/10.1024/0301-1526/a000186
  19. Schulman S. Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of thrombosis and haemostasis: JTH. 2005;3(4):692-694. https://doi.org/10.1111/j.1538-7836.2005.01204.x
  20. Paget J. Clinical lectures and essays. London: Green, 1875.
  21. Von Schroetter L. Erkankungen der Gefasse. In: Nathnagel Handbuch der Pathologie und Therapie. Wein: Holder, 1884.
  22. Tilney NL, Griffiths HJG, Edwards EA. Natural history of major venous thrombosis of the upper extremity. Arch Surg. 1970;101:792-796. https://doi.org/10.1001/archsurg.1970.01340300148026
  23. Sardar P, Chatterjee S, Lavie CJ, Giri JS, Ghosh J, Mukherjee D, Lip GY. Risk of major bleeding in different indications for new oral anticoagulants: Insights from a metaanalysis of approved dosages from 50 randomized trials. Int J Cardiol. 2015;179:279-287. https://doi.org/10.1016/j.ijcard.2014.11.101
  24. Vanassche T, Hirsh J, Eikelboom JW, Ginsberg JS. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thromb Haemost. 2014;112:918-923. https://doi.org/10.1160/TH14-04-0346
  25. Eerenberg ES, Middeldorp S, Levi M, Lensing AW, Büller HR. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of thrombosis and haemostasis: JTH. 2015;13(9):1590-1596. https://doi.org/10.1111/jth.13051
  26. Schastlivtsev IV, Lobastov KV, Barinov VE, Vorontsova AV, Tsaplin SN, Barinova IV, Boyarintsev VV. The Effectiveness and the Safety of Rivaroxaban in Comparison with Vitamin K Antagonists During the Long-Term Treatment of Venous Thrombosis/ Effektivnost’ i bezopasnost’ rivaroksabana v sravnenii s antagonistami vitamina K pri dlitel’noi terapii venoznogo tromboza. Flebologiya. 2016;1:19-28. (In Russ)..] https://doi.org/10.17116/flebo201610119-28
  27. Prandoni P, Ageno W, Mumoli N., Zanatta N, Imberti D, Visona A, Ciammaichella M, Simioni L, Cappelli R, Bucherini E, Di Nisio M, Avruscio G, Camporese G, Parisi R, Cuppini S, Turatti G, Noventa F, Sarolo L. Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. Thromb Res. 2017;153:97-100. https://doi.org/10.1016/j.thromres.2017.03.022
  28. Jeraj L, Jezovnik M, Poredos P. Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome. Thrombosis Research. 2017;157:46-48. https://doi.org/10.1016/j.thromres.2017.05.029
  29. Utne KK, Dahm A, Wik HS, Jelsness-Jørgensen LP, Sandset PM, Ghanima W. Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. Thromb Res. 2018;163:6-11. https://doi.org/10.1016/j.thromres.2018.01.013
  30. Montiel FS, Ghazvinian R, Gottsäter A, Elf J. Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J. 2017;15:26. https://doi.org/10.1186/s12959-017-0149-x
  31. Houghton DE, Bott-Kitslaar DM, Vargas E, Hodge DO, Ransone TR, Casanegra A, Peterson L, McBane RD, Wysokinski WE. Safety and Efficacy of Apixaban and Rivaroxaban for the Treatment of Upper Extremity Deep Vein Thrombosis. Blood. 2017;130(Suppl 1):2137.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.